Shionogi agrees to end Japanese cefcapene patent disputes
This article was originally published in Scrip
Shionogi has decided to reach settlements with two companies in Japan that it had taken legal action against over what it saw as the infringement of a patent for the crystal form of its oral cephalosporin Flomox (cefcapene pivoxil).
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.